Charting a 17-Month Roadmap for NeuroVive’s Development and Commercialisation
As CardioCrown wraps up the Strategic Planning phase with the SBC Catalyzer, the company is positioned to implement a well-defined plan for the development and commercialisation of NeuroVive. On the 1st of May, co-founders Victor Harabari and Heraldas Gaspariunas presented a comprehensive 17-month roadmap, marking a significant milestone for the company.
The SBC Catalyzer programme, supported by Stevenage Bioscience Catalyst, is a 6-week intensive initiative designed to help companies innovating in human health refine their commercialisation strategies. It utilises the Triple Chasm framework, allowing participants to analyse critical meso-economic vectors essential for successful market entry.
Heraldas shared his thoughts on the programme, stating, “The insights and feedback we received during this intensive phase have been invaluable. It has not only sharpened our approach to commercialisation but also expanded our understanding of the market dynamics we need to navigate.”
Throughout the programme, CardioCrown engaged in a series of highly interactive sessions that covered various strategy vectors, including market space definition, proposition framing, and funding strategy. This collaborative effort provided the team with a refined commercialisation strategy, a clear execution plan, and access to a network of experts, potential partners, and investors.
Victor echoed this sentiment, adding, “Our presentation of the 17-month roadmap was a culmination of intensive work and collaboration. The support from our mentors has been instrumental in shaping our strategy and aligning it with the market needs. We are excited to take these next steps forward in our journey.”
The feedback and support from mentors played a crucial role in the success of the programme. CardioCrown extends its gratitude to Marco Delise , and Dr. Sally Ann Forsyth at Stevenage Bioscience Catalyst, as well as Uday Phadke and Sam Dods from Triple Chasm, for their guidance throughout this transformative experience.
With the knowledge and resources gained from the SBC Catalyser programme, CardioCrown is now equipped to execute its strategic plan, ensuring the successful development and commercialisation of NeuroVive. The team is optimistic about the future and looks forward to making a meaningful impact in the health tech sector.
